Titan Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
TTNP Titan Pharmaceuticals Inc
BAC Bank of America Corp
ECF Ellsworth Growth and Income Fund Ltd
EBF Ennis Inc
EARN Ellington Residential Mortgage REIT
DXC DXC Technology Co
DX Dynex Capital Inc
DVYE iShares Emerging Markets Dividend ETF
DUK Duke Energy Corp
DTH WisdomTree International High Dividend Fund
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

Closing Price
$0.1899
Day's Change
0.0234 (14.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.2144
Day's Low
0.156
Volume
(Average)
Volume:
118,413,202

10-day average volume:
114,348,401
118,413,202
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.